Literature DB >> 25398833

JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.

Shuichi Shirane1, Marito Araki2, Soji Morishita2, Yoko Edahiro1, Hiraku Takei3, Yongjin Yoo4, Murim Choi4, Yoshitaka Sunami1, Yumi Hironaka1, Masaaki Noguchi5, Michiaki Koike6, Naohiro Noda7, Akimichi Ohsaka2, Norio Komatsu8.   

Abstract

Entities:  

Keywords:  CALR; JAK2; Japanese myeloproliferative neoplasm patients; MPL mutation

Mesh：

Substances：

Year:  2014        PMID： 25398833      PMCID： PMC4803122          DOI： 10.3324/haematol.2014.115113

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Authors:  Yoko Edahiro; Soji Morishita; Kochi Takahashi; Yumi Hironaka; Yuriko Yahata; Yoshitaka Sunami; Shuichi Shirane; Miyuki Tsutsui; Masaaki Noguchi; Michiaki Koike; Kiyotoshi Imai; Keita Kirito; Naohiro Noda; Yuji Sekiguchi; Satoshi Tsuneda; Akimichi Ohsaka; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

2.  Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment.

Authors:  R Fu; M Xuan; Y Zhou; T Sun; J Bai; Z Cao; L Zhang; H Li; D Zhang; X Zhang; C Lv; F Xue; X Liu; R Yang; L Zhang
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

3.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

Authors:  Mario Cazzola; Robert Kralovics
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

4.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

7.  Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

Authors:  Elisa Rumi; Daniela Pietra; Paola Guglielmelli; Roberta Bordoni; Ilaria Casetti; Chiara Milanesi; Emanuela Sant'Antonio; Virginia Ferretti; Alessandro Pancrazzi; Giada Rotunno; Marco Severgnini; Alessandro Pietrelli; Cesare Astori; Elena Fugazza; Cristiana Pascutto; Emanuela Boveri; Francesco Passamonti; Gianluca De Bellis; Alessandro Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

10.  Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.

Authors:  J Chi; K A Nicolaou; V Nicolaidou; L Koumas; A Mitsidou; C Pierides; M Manoloukos; K Barbouti; F Melanthiou; C Prokopiou; G S Vassiliou; P Costeas
Journal:  Leukemia       Date:  2013-12-24       Impact factor: 11.528
View more
  16 in total

1.  Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Authors:  Yasutaka Fukuda; Marito Araki; Kouji Yamamoto; Soji Morishita; Tadaaki Inano; Kyohei Misawa; Tomonori Ochiai; Yoko Edahiro; Misa Imai; Hajime Yasuda; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

2.  Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.

Authors:  Munazza Rashid; Rifat Zubair Ahmed; Shariq Ahmed; Muhammad Nadeem; Nuzhat Ahmed; Tahir Sultan Shamsi
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-09       Impact factor: 0.900

3.  Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.

Authors:  Koki Ueda; Kazuhiko Ikeda; Takayuki Ikezoe; Kayo Harada-Shirado; Kazuei Ogawa; Yuko Hashimoto; Takahiro Sano; Hiroshi Ohkawara; Satoshi Kimura; Akiko Shichishima-Nakamura; Yuichi Nakamura; Yayoi Shikama; Tsutomu Mori; Philip J Mason; Monica Bessler; Soji Morishita; Norio Komatsu; Kotaro Shide; Kazuya Shimoda; Shuhei Koide; Kazumasa Aoyama; Motohiko Oshima; Atsushi Iwama; Yasuchika Takeishi
Journal:  Blood Adv       Date:  2017-06-14

4.  Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Authors:  Kyohei Misawa; Hajime Yasuda; Marito Araki; Tomonori Ochiai; Soji Morishita; Shuichi Shirane; Yoko Edahiro; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2018-02-20       Impact factor: 2.490

Review 5.  Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.

Authors:  N Saki; R Shirzad; F Rahim; A Saki Malehi
Journal:  Clin Transl Oncol       Date:  2017-02-15       Impact factor: 3.405

Review 6.  Treatment options and pregnancy management for patients with PV and ET.

Authors:  Yoko Edahiro
Journal:  Int J Hematol       Date:  2022-04-08       Impact factor: 2.490

7.  Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.

Authors:  Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2021-07-30       Impact factor: 3.673

8.  Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Authors:  Larysa Poluben; Maneka Puligandla; Donna Neuberg; Christine R Bryke; Yahsuan Hsu; Oleksandr Shumeiko; Xin Yuan; Olga Voznesensky; German Pihan; Miriam Adam; Ernest Fraenkel; Roni Rasnic; Michal Linial; Sergiy Klymenko; Steven P Balk; Paula G Fraenkel
Journal:  Am J Hematol       Date:  2018-10-31       Impact factor: 10.047

9.  MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

Authors:  Shunichiro Yasuda; Satoru Aoyama; Ryoto Yoshimoto; Huixin Li; Daisuke Watanabe; Hiroki Akiyama; Kouhei Yamamoto; Takeo Fujiwara; Yuho Najima; Noriko Doki; Emiko Sakaida; Yoko Edahiro; Misa Imai; Marito Araki; Norio Komatsu; Osamu Miura; Norihiko Kawamata
Journal:  Int J Hematol       Date:  2021-06-24       Impact factor: 2.490

10.  Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.

Authors:  K-H Lim; Y-C Chang; C Gon-Shen Chen; H-C Lin; W-T Wang; Y-H Chiang; H-I Cheng; N-W Su; J Lin; Y-F Chang; M-C Chang; R-K Hsieh; Y-Y Kuo; W-C Chou
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.